EVI-GENORET - Functional Genomics of the Retina in Health and Disease (FP6-LIFESCIHEALTH) (2005-04-01 - 2009-03-31) (»add to infobox)

Thomas H. WHEELER-SCHILLING, Jose Alain SAHEL, Shomi BHATTACHARYA, Eberhart ZRENNER, Rui BERNARDES, Valeria MARIGO, Ronald ROEPMAN, Theodorus VAN VEEN, Angelo Luigi VESCOVI, Veronica VAN HEYNINGEN, Marius UEFFING, Andreas GAL, Charlotte REMÉ, Frank G. HOLZ, Peter HUMPHRIES, Christina FASSER, Frank MUELLER, Geraoid TUOHY, Usha CHAKRAVARTHY, Pascal DOLLE, Kader THIAM, Carmen AYUSO, Nicholas ANAGNOU, Laure-Emmanuelle BENHAMOU

EUROPEAN VISION INSTITUTE - EEIG (BE100 - Arr. de Bruxelles-Capitale) (Belgium), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR101 - Paris) (France), UNIVERSITY COLLEGE LONDON (UKI11 - Inner London - West) (Great Britain), EBERHARD-KARLS UNIVERSITAET TUEBINGEN (DE142 - Tübingen, Landkreis) (Germany), AIBILII - ASSOCIACAO DE APOIOAO INSTITUTO BIOMEDICO DE INVESTIGACAO DA LUZ E IMAGEM (PT162 - Baixo Mondego) (Portugal), FONDAZIONE TELETHON (ITE43 - Roma) (Italy), RADBOUD UNIVERSITEIT NIJMEGEN - STICHTING KATHOLIEKE UNIVERSITEIT (NL223 - Arnhem/Nijmegen) (Netherlands), LUNDS UNIVERSITET (SE044 - Skåne län) (Sweden), UNIVERSITA DEGLI STUDI DI MILANO - BICOCCA (ITC45 - Milano) (Italy), MEDICAL RESEARCH COUNCIL (UKI11 - Inner London - West) (Great Britain), GSF - FORSCHUNGSZENTRUM FUER UMWELT UND GESUNDHEIT GMBH (DE21 - Oberbayern) (Germany), UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF (DE600 - Hamburg) (Germany), UNIVERSITAET ZUERICH (CH04 - Zürich) (Switzerland), RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAET BONN (DEA22 - Bonn, Kreisfreie Stadt) (Germany), THE PROVOST FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELISABETH NEAR DUBLIN (IE021 - Dublin) (Ireland), RETINA INTERNATIONAL (CH04 - Zürich) (Switzerland), FORSCHUNGSZENTRUM JUELICH GMBH (DEA26 - Düren) (Germany), GENABLE TECHNOLOGIES LIMITED (IE021 - Dublin) (Ireland), QUEEN'S UNIVERSITY BELFAST (UKN01 - Belfast) (Great Britain), CENTRE EUROPEEN DE RECHERCHE EN BIOLOGIE ET MEDECINE (FR421 - Bas-Rhin) (France), GENOWAY SA (FR716 - Rhône) (France), FUNDACION JIMENEZ DIAZ (ES300 - Madrid) (Spain), NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS (GR300 - Attiki) (Greece), INSERM - TRANSFERT SA (FR101 - Paris) (France)

The retina is a highly complex biological system that accommodates both numerous tissue-specific and ubiquitously expressed developmental and pathologic pathways. The number of genes identified in Inherited Retinal Degenerations (IRD) has steadily increased. The commonest cause of blindness, (12.5 Million affected in Europe) Age-Related-Macular-Degeneration (ARMD), is likely to depend on both mostly unknown genetic and modifying factors. Preventing blindness from IRD and ARMD requires the understanding of the genetic and cellular interactions controlling retinal development, maintenance and function. In EVI-GENORET 24 academic and industrial partners form five interacting components (phenotyping, gcnotyping, development, therapy and functional gene analysis) to establish working platforms, share tools and knowledge within and outside the academic community (dissemination through patient organisations and transfer to industrial partners). This IP, spanning from the biology of seeing to the fight against retinal blindness, will implement an accurate clinical and molecular classification of disease, identify novel retinal genes and pathways and define the context dependent functions of these genes in normal and degenerating tissue. We will employ transcriptome, proteomics, protcin-interactome analyses, functional cellular and biochemical assays, biomformatics and model organisms to analyse patterns of gene expression and gene function in retinal development, normal function and degeneration. The unique knowledge base on molecular networks thus generated will facilitate identification and validation of novel therapeutic targets, of broad interest. Developing stem cell culture methods and new approaches to gene and drug delivery mechanisms should provide novel tools for therapy after testing in this privileged organ. An effective project management is ensured by the creation of the European Vision Institute (EVI), a EEIG devoted to #

PERSONS (24/24)

RELATED NAVIGATION AREA(S) (1/1)